Chemical formula: C₈H₈N₄ Molecular mass: 160.176 g/mol PubChem compound: 3637
Hydralazine is a direct acting vasodilator which exerts its effects principally on the arterioles. Its precise mode of action is not known.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C02DB02 | Hydralazine | C Cardiovascular system → C02 Antihypertensives → C02D Arteriolar smooth muscle, agents acting on → C02DB Hydrazinophthalazine derivatives |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| HYDRALAZINE Powder for concentrate for solution for injection/infusion | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| HYDRAZALINE Film-coated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Hydralazine is an active ingredient of these brands:
United States (US)
Australia (AU)
Brazil (BR)
Canada (CA)
Germany (DE)
Hong Kong (HK)
Ireland (IE)
Japan (JP)
Malta (MT)
Mexico (MX)
New Zealand (NZ)
Nigeria (NG)
Singapore (SG)
South Africa (ZA)
Spain (ES)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
